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Immaturity of the immune system contributes to poor vaccine responses in early life.
Germinal center (GC) activation is limited due to poorly developed follicular dendritic
cells (FDC), causing generation of few antibody-secreting cells (ASCs) with limited
survival and transient antibody responses. Herein, we compared the potential of five
adjuvants, namely LT-K63, mmCT, MF59, IC31, and alum to overcome limitations of the
neonatal immune system and to enhance and prolong responses of neonatal mice to a
pneumococcal conjugate vaccine Pnc1-TT. The adjuvants LT-K63, mmCT, MF59, and
IC31 significantly enhanced GC formation and FDC maturation in neonatal mice when
co-administered with Pnc1-TT. This enhanced GC induction correlated with significantly
enhanced vaccine-specific ASCs by LT-K63, mmCT, and MF59 in spleen 14 days
after immunization. Furthermore, mmCT, MF59, and IC31 prolonged the induction of
vaccine-specific ASCs in spleen and increased their persistence in bone marrow up to
9 weeks after immunization, as previously shown for LT-K63. Accordingly, serum Abs
persisted above protective levels against pneumococcal bacteremia and pneumonia.
In contrast, alum only enhanced the primary induction of vaccine-specific IgG Abs,
which was transient. Our comparative study demonstrated that, in contrast to alum,
LT-K63, mmCT, MF59, and IC31 can overcome limitations of the neonatal immune
system and enhance both induction and persistence of protective immune response
when administered with Pnc1-TT. These adjuvants are promising candidates for early
life vaccination.
Keywords: vaccination, neonate, adjuvant, germinal center, antibody-secreting cell persistence, spleen, bone
marrow, protective antibodies
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INTRODUCTION
Vaccines against infectious diseases have a major impact
on human health, preventing each year 2–3 millions deaths
worldwide (1). In 2017 5.4 million children under 5 years
died, mostly in developing countries, whereof 2.5 million deaths
occurred in the first month of life (2). Infectious diseases
caused a large part of these deaths, many of which are vaccine-
preventable (2). These numbers emphasize the need for effective
approaches to limit infections and preventable deaths in early
life. Vaccination is the most efficacious way to fight infection and
eliminate pathogens.
The neonatal immune system is immature resulting in
increased vulnerability to infections and poor vaccine-induced
immune responses in early life. Although protective vaccines
against many pathogens are available, the vaccine-induced
antibody (Ab) responses wane after 6–9 months, and hence
multiple vaccinations are essential to maintain protection and
immunological memory (3).
The immune system of 1 week old mice and responses
to various antigens (Ag) correspond well to those of human
neonates, both in terms of Ab responses and T cell function,
and those of 3 weeks old mice correspond to human infants
(4, 5). Induction of germinal centers (GCs) is delayed in spleen
of human neonates (6, 7), in agreement with the limited follicular
dendritic cell (FDC) maturation and GC induction in neonatal
mice (8, 9). Furthermore, the delayed induction of T follicular
helper cells (Tfh) is circumvented by adjuvants like MF59 in
infant but not neonatal mice (10). Similarily, Tfh response
was limited in naive children (11), but MF59 increased IFNγ+
and TNFα+IL-2+ secreting CD4+ T cells in human infants
vaccinated with tri-valent influenza vaccine (12). We have shown
that immunogenicity of pneumococcal conjugate vaccine is
highly age dependent and plain pneumococcal polysaccharide
(PPS) is only immunogenic in adult mice but not infant or
neontal mice, reproducing the main features of human infant
immune responses to native capsular PPS and pneumococcal
conjugate vaccines, as well as the relative protective efficacy of
those vaccines. In ourmousemodel of pneumococcal vaccination
and infection LT-K63 enhanced the response to Pnc1-TT but not
to the polysaccharide in neonatal and infant mice, in line with its
effect on the FCDs and GCs which play a key role in response
to T cell-dependent (TD) Ags but not T cell-independent (TI)
Ags (9, 13–15).
Neonatal activation of GCs is limited leading to formation
of few plasmablasts whose survival in bone marrow (BM)
is reduced, resulting in low and transient Ab responses (16,
17). In GCs, B cells undergo clonal expansion and affinity
maturation, and consequently the differentiation into Ab-
producing plasmablasts and plasma cells (PC) or memory cells.
FDCs can bind and present Ag-Ab immune complexes to B cells
via complement receptors or Fc receptors (18, 19). FDCs together
with Tfh orchestrate the GC reaction. The crosstalk between
GC B cells and Tfh influences B cell survival, proliferation and
differentiation and promotes development of memory B cells
and long-lived PCs (20). Interestingly, there is a preferential
differentiation of memory B cells rather than PCs in neonates
[reviewed in (4)]. Most plasmablasts emerging from neonatal
GCsmigrate efficiently to the BM, but do not persist. Instead they
undergo apoptosis resulting in rapid decline of serum Abs during
early life (16, 21). This is explained by insufficient survival signals,
mainly APRIL, from the BM niches, leaving the plasmablasts
unable to differentiate into long-lived PCs and persist in the BM
niche (16, 21, 22).
Adjuvants are immune stimulating agents and are central
components of vaccines that enhance both magnitude and
duration of immune responses and may modulate the nature of
the responses. Alum was the only adjuvant included in licensed
human infant vaccines until MF59 was included in H1N1
influenza vaccine licensed in Europe in 2009 for vaccination from
6 months of age (23, 24). The adjuvant LT-K63 is a non-toxic,
genetically modified derivative of heat labile enterotoxin from
E. coli, that interacts with a variety of immunocompetent cells
and mediates immunomodulation associated with adjuvanticity.
LT-K63 was originally developed as a mucosal adjuvant but also
elicited strong adjuvanticity when given parenterally [reviewed
in (13, 14, 25)]. We showed for the first time that LT-K63
could stimulate GC formation and enhance maturation of FDC
network in neonatal mice. Immunization of neonatal mice with
Pnc1-TT and LT-K63 resulted in increased Ab responses and
increased specific ASCs in spleen and survival in BM, leading
to persistence of protective Abs against pneumococcal lung
infection and bacteremia (9, 13, 14). We have previously shown
that Pnc1-TT with LT-K63 or CpG-ODN induced comparable
protective Ab levels and had comparable effects on neonatal
dendritic cells, B cells and T cells (26–28). However, only LT-K63
improved T helper cell type 1 (Th1) activation (26, 28), increased
TNF expression associated with enhanced FDC maturation, GC
induction and prolonged persistence of ACSs in spleen and BM
[(9) and unpublished data]. The clinical development of LT-K63
was stopped due to transient facial nerve paralysis observed in
two vaccinees following intranasal delivery (29). Recently, the
ability of the adjuvant, CAF01 to induce GC reaction in neonatal
mice was reported (30). There is an unmet need of developing
safe and potent adjuvants that can overcome the limitations
of early life immunity (31). Further, a better understanding
of the mode of action of existing adjuvants may contribute
to development of improved neonatal and infant vaccination
strategies (32).
In search for an optimal neonatal adjuvant we evaluated the
potential adjuvant effect of four adjuvants with different modes
of action, namely mmCT,MF59, IC31, and CTB-CpG, on various
neonatal immune parameters, with emphasis on GC induction,
FDC maturation, and the generation of ASCs in the spleen, their
migration to and long-term survival in the BM, translating into
persistent protective Ab levels. Alum and LT-K63 were used for
comparison. mmCT is a novel, non-toxic multiple-mutant of
cholera toxin (CT) (33) that in addition to increasing IgG and
IgA Ab responses to co-administered antigen and strong IFN-γ
and IL-17A T cell responses in mice (34), it has been shown to
promote human Th17 responses (35) through activation of the
classical NF-κB pathway of monocytes (36). MF59, a squalene-
based oil-in-water emulsion, was well tolerated and enhanced
protective efficacy of influenza vaccination in infants and young
children (37), meeting all the European licensure criteria (38)
and has been licensed for use in children from 6 months with
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seasonal influenza vaccine (23). IC31, which combines two
immunomodulatory compounds; an antibacterial peptide KLK
(11-mer cationic peptide KLKL5KLK) and a TLR9 agonist, a
synthetic oligodeoxynucleotide (ODN1a) without a CpG motif,
has been shown to rapidly enhance protective humoral responses
in neonates when combined with Pnc1-TT (39). CTB-CpG is a
potent novel adjuvant that combines the effects of CpG and the
non-toxic B subunit of cholera toxin (40, 41). Our comparative
study shows that LT-K63, mmCT, MF59 and IC31 can overcome
limitations of the neonatal immune system and enhance both
induction and persistence of protective immune responses when
administered with Pnc1-TT.
MATERIALS AND METHODS
Mice
Adult NMRI mice were purchased from Taconic (Skensved,
Denmark) and allowed to adapt for 1 week before mating. They
were kept in microisolator cages with free access to commercial
food pellets and water, and housed under standardized
conditions at ArcticLAS vivarium facility (Reykjavík, Iceland),
with regulated daylight, humidity and temperature. Breeding
cages were checked daily for new births, and pups kept with
their mothers until weaning at 4 weeks of age. This study
was carried out in accordance with the Act No. 55/2013
on animal welfare and regulations 460/2017 on protection
of animals used for scientific research. The protocol was
approved by the Experimental Animal Committee of Iceland
(license no. 2015-10-01).
Vaccine and Adjuvants
PPS of serotype 1 (PPS1) conjugated to TT (Pnc1-TT) (42)
was provided by Sanofi Pasteur (Marcy l’Etoile, France). LT-
K63 and MF59 were produced by Novartis Vaccines and
Diagnostics, (now GSK Vaccines, Siena, Italy) as described
previously (43, 44). mmCT and CTB-CpG were produced as
described elsewhere (33, 45). IC31 was produced by Intercell AG,
(now Valneva, Vienna, Austria) as described (46). Aluminum
hydroxide (Alhydrogel) was purchased from Brenntag Biosector
A/S (Ballerup, Denmark).
Immunizations
Neonatal (1 week old) mice (8 mice/group, except 3–
4 mice/group in a screening experiment) were immunized
subcutaneously (s.c.) at base of tail with 0.5 µg of Pnc1-TT alone
or mixed with the adjuvants LT-K63 (5 µg/mouse), mmCT (2
µg/mouse), MF59 (50% of injected volume/mouse), IC31 (50
nmol KLK and 2 nmol ODN1a/mouse), CTB-CpG (5µg/mouse),
or Alum (0.48% aluminum hydroxide per 1µg of protein/mouse)
in 50 µl of saline. We compared s.c. immunizations at scapular
girdle as used in earlier studies (9, 13, 14, 26, 39) with s.c.
immunization at base of tail and observed no difference between
the routes, as comparable GC induction was observed in the
spleen along with comparable vaccine-specific ASC in spleen and
BM and Abs in serum (Figure S1), indicating that independent
of the s.c. immunization site and draining LNs, the efficiency of
Ag transport to the spleen is similar.
Blood was obtained from the tail vein at various time points
after priming; serum was isolated and stored at −20◦C. Spleens
were removed and half was mounted in OCT, snap frozen, and
kept at −70◦C; the other half was used to enumerate PPS1
and TT-specific ASCs. BM was collected for enumeration of
specific ASCs.
ELISA
PPS1- and TT-specific Abs (IgG) were measured by ELISA (47).
Microtiter plates (MaxiSorp; Nunc AS, Roskilde, Denmark) were
coated with 5 µg PPS1/ml (American Type Culture Collection,
Rockville, MD) in PBS for 5 h at 37◦C or 5 µg TT (Sanofi
Pasteur) per milliliter in 0.10M carbonate buffer (pH 9.6)
overnight at 4◦C and blocked with PBS-Tween 20 and 1%
BSA (Sigma). Serum samples and standard were neutralized by
cell wall polysaccharides (Statens Serum Institute, Copenhagen,
Denmark). Neutralized sera and standard in duplicates were
serially diluted (3-fold dilutions) and were incubated at
room temperature for 2 h, followed by HRP goat anti-mouse
Ab (Southern Biotechnology Associates, Birmingham, AL).
The reaction was developed by 3,3′,5,5′-tetramethylbenzidine-
substrate (Kirkegaard & Perry Laboratories, Gaithersburg,
MD), stopped with 0.18M H2SO4, and read at 450 nm in
Titertek Multiscan Plus MK II spectrophotometer (ICN Flow
Laboratories, Irvine, U.K.). Results were expressed as mean log
ELISA units (EU)/ml ± SD, calculated from a standard curve
from at least two different dilutions with coefficient of variation
between duplicates and dilutions below 20% (47).
ELISPOT
PPS1- and TT-specific ASC were enumerated by ELISPOT,
as previously described (9, 48). MultiScreen High protein
binding immobilon-P membrane plates (Millipore Corporation,
Bedford, MA) were coated with 20µg/ml PPS1 or 10µg/ml
TT overnight at 37◦C, blocked with complete RPMI 1640
(Life Technologies BRL, Life Technologies, Paisley, U.K.).
Duplicates of cells from spleen and BM were tested in four
three-fold dilutions starting with 1 × 107 cells in 100 µL
in complete RPMI 1640 per well (9, 48) and incubated
for 5 h at 37◦C, washed and incubated with ALP-goat anti-
mouse IgG (Southern Biotechnology Associates) overnight at
4◦C, and developed by 5-bromo-4-chloro-3-indolylphosphate
and NBT in AP development buffer (Bio-Rad Labs, Hercules,
CA). The number of spots, each representing a cell secreting
specific Abs, were counted by ELISPOT reader ImmunoSpot R©
S6 ULTIMATE using ImmunoSpot R© SOFTWARE (Cellular
Technology Limited (CTL) Europe, Bonn, Germany).
Immunofluorescent Staining of Tissue
Sections
Spleens were frozen in Tissue-Tek OCT (Sakura, Zouterwoude,
the Netherlands) and cut into 7µm cryosections at 2 levels,
starting 1,750µm into the tissue; the levels were separated by
210µm, fixed in acetone for 10min, and stored at −70◦C.
Two sections/spleen (one from each level) were stained with
fluorescent labeled IgM-FITC (BD Pharmingen) to visualize the
follicles, and biotinylated peanut agglutinin (PNA)-bio (Vector
Frontiers in Immunology | www.frontiersin.org 3 September 2019 | Volume 10 | Article 2214
Aradottir Pind et al. Adjuvants Enhancing Neonatal ASC Persistence
Laboratories, Burlingame, CA) to label dark-zone B cells, a
good marker for active GC reaction. Adjacent sections from
both levels of spleen were stained with primary monoclonal
Abs (mAbs) FDC-M2 (biotinylated) (AMS Biotechnology
Limited, Oxfordshire, U.K) for mature FDCs and MOMA-1
(AbD Serotec, Düsseldorf, Germany) for metallophilic marginal
macrophages, respectively. Primary Abs were incubated at
RT for 30min. The sections were then washed in PBS for
2 × 5min prior to incubation with APC Streptavidin (BD
Biosciences, Stockholm, Sweden) at RT for another 30min and
sections washed again as before. DAPI (Invitrogen, Eugene,
OR) was used for nuclear counterstaining. The sections were
photographed with a digital camera (AXIOCAM; Zeiss) in a
microscope (Zeiss) equipped with X10 and X40 20 objectives
and AxioImaging Software (Birkerod, Denmark) for light and
three-color immunofluorescence. Areas of PNA- and FDC-M2-
positive staining were measured from all pictures using the
AxioImaging Software.
Statistical Analysis
Mann-Whitney U test was used for comparison between groups.
Results were considered significant at p < 0.05. All statistical
analyses were carried out using Graphpad Prism 7.03 (GraphPad
Software, La Jolla, CA).
RESULTS
Screening and Selection of Adjuvants
First, we screened for potential effects of the adjuvants mmCT,
MF59, IC31, and CTB-CpG on the neonatal immune response
compared to the previously established effects of LT-K63 (9)
on the induction of GC reaction and enhanced Ab response
in neonates. Neonatal mice were immunized s.c. with Pnc1-
TT, with/without adjuvants. GC activation and maturation of
FDC in spleen was assessed 14 days after immunization and
vaccine-specific Abs in serum measured 14 and 35 days after
immunization. Immunofluorescent staining revealed thatmmCT
and MF59 enhanced GC formation in spleen to a comparable
degree as LT-K63 (Figure S2). Accordingly, mmCT, MF59,
and IC31 yielded comparable Ab responses as that induced
by LT-K63, while CTB-CpG did not increase Ab responses
compared to Pnc1-TT alone (Figure S3). Based on those results
(Figures S2, S3) mmCT, MF59, and IC31 were selected for
further evaluation of their effects on primary B cell induction
and humoral response compared to those of LT-K63 and alum.
As CTB-CpG seemed to neither enhance the GC activation nor
vaccine-specific Abs it was not included in further experiments.
LT-K63, mmCT, MF59, and IC31 Enhance
Induction of GCs in Neonatal Mice
Neonatal mice were immunized with Pnc1-TT with or without
LT-K63, mmCT, MF59, IC31, or alum. Spleen sections were
stained with anti-IgM and PNA to evaluate the adjuvant effects
on GC induction 14 days after immunization. IgM staining
detects naïve B cells in the follicles and PNA staining identifies
highly proliferating B cell centroblasts located in the dark zone
of the GCs. Compared to Pnc1-TT alone, all adjuvants except
alum significantly enhanced GC formation, demonstrated by
increased PNA/IgM ratio (Figure 1A, Figure S4, and Table S1),
increased total area of PNA+ staining and average size of GCs
(Figure 1B, Figure S4E, and Table S1). PNA staining patterns
of representative individuals for each group (Figure 1C) showed
a clear difference between mice immunized with Pnc1-TT with
LT-K63, mmCT, MF59, or IC31 compared to Pnc1-TT only.
The PNA staining was intense in the adjuvant groups with
distinctive formation of PNA+ follicles. In contrast, mice that
received only Pnc1-TT had few, faint, small and poorly formed
PNA+ GCs. The Pnc1-TT + alum group also showed weak GC
staining, similar to that of mice immunized with Pnc1-TT alone.
Therefore, in contrast with alum, neonatal immunization with
LT-K63, mmCT, MF59, or IC31 combined with Pnc1-TT could
overcome the early life limitations of GC induction.
The Impact of LT-K63, mmCT, MF59, and
IC31 on FDC Maturation and Metallophilic
Macrophage Migration Into Splenic B Cell
Follicles in Neonates
To explore whether adjuvant-enhanced GC formation was
mediated by accelerated FDC network maturation, spleen
sections obtained 14 days after priming with Pnc1-TT
with/without adjuvant were stained with anti-FDC-M2 that
identifies complement fragment C4 on mature immune-
complex-bearing FDCs (49). To assess if the adjuvants
induce migration of immune complex/Ag-bearing marginal
metallophilic macrophages (MMM) into activated follicles,
spleen sections were stained for MOMA-1 (CD169), a lectin-
like receptor expressed on different macrophages populations
including splenic MMMs and subcapsular macrophages of LNs
(50, 51). MOMA-1+ macrophages show migratory properties
in response to bacterial stimuli like LPS (52). LT-K63, mmCT,
MF59, and IC31 significantly enhanced maturation of FDC-M2+
FDC clusters in spleen, shown by increased FDC-M2/IgM
ratio, compared to vaccine alone (Figure 2A and Table S1).
All these adjuvants also significantly enhanced the total area
of FDC-M2+ staining (Figure 2B and Table S1) and average
size of FDC-M2+ FDC clusters (Figure S1F). However, alum
had no effect on number or size of FDC-M2+ FDC clusters in
spleen. MOMA-1 staining revealed that LT-K63, MF59, and IC31
significantly enhanced the migration of MMMs into follicles
where they co-localized with FDC-M2+ FDCs, demonstrated
by MOMA-1/IgM ratio, compared to vaccine alone (Figure 2C
and Table S1), whereas the effects of mmCT and alum on
MOMA-1/IgM ratio were not significant. Immunofluorescence
staining patterns of representative individuals from each group
(Figure 2D) show that neonatal mice immunized with Pnc1-TT
with LT-K63, mmCT, MF59, or IC31 had well formed FDC-M2+
clusters, with intense and even staining, while LT-K63 had the
strongest effect on MMM migration into the activated follicles.
In contrast, the Pnc1-TT+ alum group showed weak staining of
FDC-M2+ clusters, similar to mice that only received Pnc1-TT.
Taken together, the adjuvants LT-K63, mmCT, MF59, and IC31
accelerated maturation of FDC-M2+ FDC clusters, in contrast
to alum where no effect was observed.
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FIGURE 1 | Effects of adjuvants on germinal center induction. Spleen sections were stained with fluorescent Abs for PNA and IgM 14 days after immunization of
neonatal mice with Pnc1-TT with/without adjuvants LT-K63, mmCT, MF59, IC31, or alum. PNA/IgM ratio represents activated GCs in relation to total number of
follicles (A) and PNA+ area represents total area of positive PNA staining per section (B). Representative immunofluorescense staining pattern for PNA (red) and IgM
(green) of each group is shown in (C). Results are expressed as mean + SD in 8–9 mice per group and statistics done using Mann–Whitney U-test where adjuvant
groups were compared to vaccine only group: *p < 0.05, **p < 0.001.
mmCT and MF59 Enhance the Induction of
Vaccine-Specific ASCs in Spleen
Next we investigated whether enhanced GC formation, evident
by PNA staining, correlated with enhanced primary induction
of vaccine-specific ASCs in spleen and consequently, enhanced
vaccine-specific Abs in serum. LT-K63, mmCT, and MF59
induced significantly higher number of PPS1- and TT-
specific ASCs than Pnc1-TT alone, in spleen 14 days after
immunization (Figures 3A,B and Table S3). All adjuvants
significantly enhanced TT-specific Abs in serum compared
to Pnc1-TT alone (Figure 3D) and mmCT, MF59, and IC31
significantly enhanced PPS1-specific Abs compared to vaccine
alone (Figure 3C and Table S2). Interestingly, immunization
with Pnc1-TT with MF59 or IC31 prolonged the induction
of PPS1-specific ASCs in spleen reflected by higher number
of PPS1-specific ASCs in spleen 6 weeks after immunization
compared to mice that received only Pnc1-TT (Figure S5 and
Table S3). Mice immunized with Pnc1-TT with MF59 still had
significantly increased numbers of PPS1-specific ASCs in spleen
up to 9 weeks later (Figure S5 and Table S3). Increased numbers
of TT-specific ASCs in spleen were also observed 9 weeks
after immunization with Pnc1-TT with mmCT, MF59, or IC31
(Figure S5 and Table S3).
mmCT, MF59, and IC31 Increase the
Persistence of Vaccine-Specific ASCs in
Bone Marrow
We have previously shown that LT-K63 enhances induction of
primary vaccine-specific ASCs and prolongs their persistence
in spleen and BM (9). Thus, to investigate the effect of
mmCT, MF59, IC31, and alum on migration and long-term
persistence of vaccine-specific ASCs in BM they were enumerated
2, 6, and 9 weeks after one neonatal immunization. Mice
immunized as neonates with Pnc1-TT with mmCT or MF59 had
already significantly increased number of TT-specific ASCs in
BM 2 weeks after immunization and mmCT also significantly
increased PPS1-specific ASC numbers in BM 6 weeks after
immunization (Figure 4 and Table S4). All adjuvants, including
alum, enhanced the numbers of TT-specific ASCs in BM 6 weeks
after administration with Pnc1-TT, compared to vaccine alone
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FIGURE 2 | Effects of adjuvants on follicular dendritic cell maturation and migration of marginal metallophillic macrophages into follicles. Spleen sections were stained
with fluorescent Abs for FDC-M2 and MOMA-1 14 days after immunization of neonatal mice with Pnc1-TT with/without adjuvants LT-K63, mmCT, MF59, IC31, or
alum. FDC-M2/IgM ratio represents number of fully developed FDC networks in relation to total follicles (A), FDC-M2+ area represents total area of positive FDC-M2
staining per section (B), and MOMA-1/IgM ratio represents count of MOMA-1+MMM migration into follicles in relation to total follicles (C). Representative
immunofluorescense staining pattern for FDC-M2 (red) and MOMA-1 (green) of each group is shown in (D). Results are expressed as mean + SD in 8–9 mice per
group and statistics done using Mann–Whitney U-test where adjuvant groups were compared to vaccine only group: *p < 0.05, **p < 0.001.
(Figure 4 and Table S4). Mice immunized with Pnc1-TT with
mmCT, MF59, or IC31 still had increased numbers of PPS1- and
TT-specific ASCs in BM 9 weeks after immunization, whereas
there was no difference between mice immunized with Pnc1-TT
only and those that received Pnc1-TT with alum. This shows that
alum-enhanced immune responses in neonatal mice are more
transient than those induced by the other adjuvants (Figure 4
and Table S4).
mmCT, MF59, and IC31 Increase the
Persistence of Vaccine-Specific Abs in
Serum
Next we assessed the adjuvant effects on Ab responses, both
primary induction and long-term persistence of Abs up to
9 weeks after immunization. All the adjuvants significantly
enhanced TT-specific Abs over the time period while all except
alum significantly enhanced PPS1-specific Abs (Figure 5 and
Table S2). Even though alum enhanced the primary induction
of vaccine-specific IgG Abs, the responses were transient and
8–9 weeks after immunization there was no difference between
serum Abs in mice immunized with Pnc1-TT only and Pnc1-
TT with alum, in contrast to the persisting increase in Ab levels
induced by the other adjuvants (Table S2). The protective PPS1-
specific IgG Ab levels of log 1.5 EU/ml and log 2.5 EU/ml against
pneumococcal bacteremia and lung infections, respectively, are
well established in this model of neonatal, infant and adult mice
when challenged intranasally with S. pneumoniae of serotype
1 (13–15, 28, 39, 53, 54). All mice that were immunized as
neonates with one dose of Pnc1-TT with mmCT, MF59, or
IC31 reached anti-PPS1 IgG levels close to 2 log EU/ml above
protective levels against pneumococcal bacteremia and close to
1 log EU/ml above protective Ab levels against lung infection,
that persisted for 9 weeks after immunization (Figure 5 and
Table S5). Taken together, our results demonstrate a superiority
of the novel adjuvants tested here compared to alum to induce
persistent protective Ab responses at early age compared to alum.
DISCUSSION
In this study, we compared the potential of mmCT, MF59, and
IC31, to overcome limitations of the neonatal immune system
and induce robust and long-lasting responses to immunization.
LT-K63 and alum were used for comparison. LT-K63, MF59,
and IC31 have previously been shown to enhance some neonatal
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FIGURE 3 | Adjuvants can induce enhanced induction of vaccine-specific antibody-secreting cells in spleen and increased induction of vaccine-specific antibodies in
serum. PPS1-specific (A,C) and TT-specific (B,D) ASC in spleen (A,B) and Abs in serum (C,D) 14 days after immunization of neonatal mice with Pnc1-TT with or
without the adjuvants LT-K63, MF59, IC31, mmCT, or alum. Results are expressed as number of spots/106 cells (mean + SD) or IgG levels (mean EU/ml + SD) in 8–9
mice per group. Statistical difference was calculated using Mann–Whitney U-test where adjuvant groups were compared to vaccine only group: *p < 0.05,
**p < 0.0001.
immune responses (9, 10, 28, 30, 55) while effects of mmCT
on neonatal immunity have not been reported. We found
that all the adjuvants except alum, enhanced neonatal immune
responses, both initiation and persistence. Our results show little
benefits of alum in early life immunization with a pneumococcal
conjugate vaccine.
LT-K63, mmCT, MF59, and IC31 all enhanced GC induction
after neonatal immunization with Pnc1-TT, shown by PNA
staining of spleen sections. Until now only LT-K63 (9), and
recently CAF01 (30) have been shown to overcome delayed
induction and elicit fully established GCs in neonates where
HA/CAF01 (30) and Pnc1-TT/LT-K63 (9) elicited organized
and well-structured GCs upon neonatal immunization. In
the current study, IC31 given with Pnc1-TT accelerated the
maturation of FDCs and induced formation of GCs. This
contrasts results from neonatal immunization with HA/IC31
where GC formation was not observed (30) and neonatal
immunization with IC31 and pneumococcal proteins, which did
neither accelerate FDC maturation nor induce GC formation
[(28) and unpublished data]. Likewise, no GCs were observed
in dLNs 10 days after immunization of neonatal mice with
HA/MF59 (10) even though they were observed in spleen 14
days post immunization with Pnc1-TT + MF59 in this study.
Furthermore, in our study GCs were almost absent when alum
was administered with Pnc1-TT, while GCs were detected in
spleen 14 days after i.p. immunization of neonatal mice with
alum-adsorbed TT in a different study (8). Thus, it seems
that not only the adjuvant but the doses and combination of
antigen and adjuvant, and possibly the immunization route,
lymphoid tissue, and mouse strain studied, affect whether adult-
like induction of GCs is observed after neonatal immunization.
In addition, the difference in the antigen used may not be trivial,
a conjugate vaccine can behave differently than an influenza
hemagglutinin. The polysaccharide is not an inherent component
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FIGURE 4 | Effects of adjuvants on migration and persistence of vaccine-specific antibody-secreting cells in bone marrow. PPS1-specific (left panel) and TT-specific
(right panel) ASC in bone marrow 2, 6, and 9 weeks after priming with Pnc1-TT with/without the adjuvants mmCT, MF59, IC31, or alum. Results are expressed as
number of spots/106 cells (mean ± SD) in 8 mice per group (except n = 7 for MF59 at week 6). Statistical difference was calculated using Mann–Whitney U-test
where adjuvant groups were compared to vaccine only group: *p ≤ 0.05, **p ≤ 0.001.
in front of the carrier, and may play a role acting directly
on B cells.
All the adjuvants tested in this study, except alum, accelerated
the maturation of FDC-M2+ FDC clusters. FDC-M2 Ab reacts
with murine FDCs and specifically recognizes an activation
form of the complement fragment C4 (49). In GCs, FDCs
retain and present immune complexes to B cells through
complement- and Fc-receptors (18). We have previously shown
that LT-K63 can restore delayed maturation of FDCs and
induce adult-like FDC-M2+ FDC clusters when administered
to neonatal mice with Pnc1-TT (9). LT-K63 is, until now,
the only adjuvant that has been reported to overcome this
delayed FDC maturation while potent adjuvants like CpG,
which induce adult-like B- T- and dendritic cell responses have
failed to do (8, 9). Although CAF01 can elicit fully established
GCs in neonates (30) its effect on neonatal FDC-M2+ FDC
maturation has not been reported. Others have proposed the
role of FDC-M1+ FDCs (56, 57) and CR1 (56, 58) in the
organization of B cell follicles and maintenance of GC in early
life, whereas our previous work did not indicate that they were
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FIGURE 5 | Kinetics of vaccine-specific IgG antibody response after neonatal immunization. PPS1- (left panel) and TT-specific (right panel) serum Abs 2, 4, 6, 8, and 9
weeks after immunization of neonatal mice with Pnc1-TT with/without the adjuvants mmCT, MF59, IC31, or alum. Results are expressed as IgG levels (EU/ml + SD).
The dotted line (log EU/ml = 1.5) represents a sufficient antibody titer to protect against serotype 1 pneumococcal bacteremia while the dashed line (log EU/ml = 2.5)
represents an antibody titer sufficient for protection against serotype 1 pneumococcal lung infection. Statistical difference was calculated using Mann-Whitney U-test
where adjuvant groups were compared to vaccine only group: *p ≤ 0.05, **p ≤ 0.001.
limiting factors for FDC network maturation (9). In agreement
with our results, i.p. immunization of neonatal mice with TT
adsorbed to AL(OH)3 did not accelerate maturation of FDC
clusters (8).
Blood-borne Ags are primarily trapped in the marginal
zone of the spleen. MZ B cells (59, 60) and MMMs have
been shown to be crucial for trapping of particulate Ags
(61) in spleen and subcapsular sinus macrophages in LNs
(50, 51). MOMA-1+ macrophages are required for immune
responses against TD and TI-2 Ags (62, 63). We observed
increased migration of MOMA-1+ macrophages that co-
localized with FDC-M2+ FDCs in mice immunized with
Pnc1-TT with LT-K63, MF59, and IC31. This correlated with
enhanced GC reaction and later increased frequencies of vaccine-
specific Abs and ASCs. However, even though enhanced GC
activation and increased frequencies of vaccine-specific ASCs
were observed in mice immunized with Pnc1-TT and mmCT,
this adjuvant did not enhance migration of MMMs into
follicles. It is possible that day 14 after immunization is not
optimal for evaluating and comparing the effects of all the
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adjuvants as they have different mechanisms of action and
different kinetics.
Ab persistence is mediated by long-lived memory PCs that
reside in specialized survival niches in the BM. It has been
noted that most of the plasmablasts emerging from the GC in
neonates migrate efficiently to the BM, but lack ability to persist.
Instead they undergo apoptosis resulting in rapid decline of
serum Abs during early life (16, 21). We found that mmCT,
MF59, and IC31 all enhanced persistence of vaccine-specific
ASCs in BM when administered with Pnc1-TT. As suspected,
increased persistency of ASCs in BM coincided with increased
levels of vaccine-specific IgG Abs. It is encouraging that only
one dose of Pnc1-TT with the adjuvants mmCT, MF59, or IC31
in neonates was enough to induce protective Ab levels against
both pneumococcal bacteremia and pneumonia (13, 53, 54) since
one of the great challenges of neonatal immunization is the need
of multiple vaccinations to induce and maintain protection and
immunological memory (3). Likewise, a single dose of HA with
adjuvants CAF01 (30) or AdvaxTM (64) administered to 7 days old
mice has been shown to be protective against influenza challenge.
We have shown the superiority of intranasal immunization
with Pnc1-TT and LT-K63 in neonatal and infant mice
compared to parenteral immunization, in terms of enhanced
specific mucosal IgA and systemic IgG and protection from
pneumococcal bacteremia and lung infection (13). mmCT is a
potent mucosal adjuvant (33–36) and here we show its effect
as a parenteral adjuvant in neonates. Potential advantage of
mucosal immunization against encapsulated respiratory bacteria
at early age needs to be further studied (65). However, parenteral
vaccination can also be effective in inducing protective responses
at mucosal sites, especially when formulated with mucosal
trafficking adjuvants, able to alter expression of mucosal homing
markers and tissue destination [reviewed in (66)].
There is still limited clinical information on the safety of
vaccine adjuvants in newborns and, more in general, in infants.
This is due to the slow process of vaccine development which
requires cautious testing first in adults, then in adolescents,
and finally in infants. Among the adjuvants tested in our
study, the largest experience has been acquired with MF59-
adjuvanted seasonal, pandemic, and avian influenza vaccines.
MF59-adjuvanted seasonal influenza vaccine had a stronger
efficacy as compared to licensed non-adjuvanted influenza
vaccines in infants (37), it was more immunogenic than the
non-adjuvanted vaccine in infants and toddlers and it exhibited
an excellent safety profile (12, 37, 67). It must be added
that cytokine profile induced by the MF59-adjuvanted vaccine
in infants did not differ from that found in adults (i.e.,
a Th0/Th1-type profile), with no evidence of induction of
Th2-type responses (12, 67). The same strong immunogenicity
was also observed with the pandemic and with avian influenza
vaccines (68). Another oil-in-water adjuvant, containing alpha-
tocopherol, referred to as AS03 (not included in this study),
was reported to be associated with the insurgence of narcolepsy
when administered with pandemic A/H1N1 vaccine in young
children (69). However, these allegations were never formally
substantiated by experimental data (70). More studies will be
required with other vaccine adjuvants to show their safety profile
in young children and ultimately in infants.
Taken together, by comparing the effects of different adjuvants
on GC reaction, ASC in spleen and BM and serum Abs
in neonatal mice we have shown that in contrast to alum,
the most widely used adjuvant in childhood vaccinations, LT-
K63, mmCT, MF59, and IC31 all enhanced GC reaction and
FDC maturation when administered with a pneumococcal
conjugate vaccine. Furthermore, LT-K63, mmCT, MF59, and
IC31 induced increased numbers of vaccine-specific ASCs
that persisted in BM 9 weeks after immunization, which was
reflected in increased vaccine-specific serumAbs persisting above
protective levels against pneumococcal disease (13, 53, 54).
This demonstrates that it is possible to achieve adult-like long-
lived responses to neonatal vaccination by the use of selected
adjuvants. These results warrant further investigation of mmCT,
MF59, and IC31 as promising candidate adjuvants for early
life vaccination.
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